Qiming Venture Partners Weekly | Top 10 Portfolio Company Updates Vol.22, June 30, 2026

Editor's Note: In 2026, the Qiming Weekly has been upgraded and refreshed, with regular weekly updates featuring only ten major developments from Qiming Venture Partners' portfolio companies, covering funding progress and breakthroughs.

In the wave of technology and innovation, every step entrepreneurs take deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and we look forward to sharing these milestone moments with you.

Major Partnerships

01/ Abbisko Therapeutics Deepens Drug Discovery Collaboration with Eli Lilly and Company

Recently, Qiming Venture Partners portfolio company Abbisko Therapeutics (02256.HK) announced that it has entered into a strategic R&D collaboration and licensing agreement with global pharmaceutical leader Eli Lilly and Company. The two parties will collaborate on innovative drug discovery across multiple disease targets, jointly advancing new drug programs with global potential. Abbisko Therapeutics and Eli Lilly will combine their respective strengths in drug discovery, R&D, and global development to accelerate the progress of innovative drug programs and bring more novel treatment options to patients worldwide.

Under the agreement, Abbisko Therapeutics will leverage its early-stage drug discovery platform and innovative R&D system, combined with its extensive new drug development experience, to conduct discovery and early-stage development of new drug programs targeting disease targets selected by Eli Lilly. Abbisko Therapeutics will receive an upfront payment and will be eligible for additional payments upon achieving development, regulatory, and commercial milestones, with a total potential value of up to $1.9 billion. In addition, Abbisko Therapeutics will be entitled to tiered royalties based on future net product sales.

02/ WeRide Signs Strategic Partnership with Geely Farizon and Kwoon Chung Bus

Recently, Qiming Venture Partners portfolio company and global leading autonomous driving technology company WeRide (NASDAQ: WRD, 0800.HK) signed a strategic partnership agreement with Geely Farizon, the #1 brand in new energy commercial vehicles, and Kwoon Chung Bus Holdings, a leading transportation operator in Hong Kong, at the 2026 International Automotive and Supply Chain Expo (Hong Kong).

**The three parties will fully leverage their core strengths in autonomous driving technology R&D, new energy vehicle manufacturing, and public transportation operations. Building on the existing frontline mass-produced Robotaxi GXR platform, they will jointly develop a natively mass-produced Robotaxi model for right-hand-drive markets, with Hong Kong as the starting point for deploying commercial Robotaxi mobility services targeting right-hand-drive markets. This marks the Robotaxi industry's first step from "regional capability" into a new era of "global adaptation," bringing revolutionary autonomous driving solutions to right-hand-drive markets worldwide.

WeRide founder and CEO Tony Han said: "Globalization has always been at the core of WeRide's strategy. We have already deployed autonomous driving operations in 12 countries and over 40 cities. We are honored to partner with Geely Farizon and Kwoon Chung Bus. This represents a major breakthrough for autonomous driving technology in complex traffic scenarios in high-density cities globally, and will lay important groundwork for our future expansion into right-hand-drive markets worldwide."

03/ Shengshu Technology and Jidou Technology Form Strategic Partnership

Recently, Qiming Venture Partners portfolio company Shengshu Technology and Jidou Technology held a strategic partnership signing ceremony at Yuan Dian Academy in Beijing's AI Origin Community, formally establishing their collaboration.

The two parties will integrate Shengshu Technology's capabilities in multimodal large models and Jidou Technology's expertise in automotive AI solutions, frontline mass production delivery, and user operations**, collaborating across scenario co-creation, platform integration, operations enablement, and ecosystem building to jointly develop AI applications for intelligent connected vehicles and AIGC solutions for the automotive industry, driving generative AI from model capability integration toward real-world scenario deployment, scaled application, and long-term operations.

04/ HyperStrong Signs Strategic Cooperation Framework Agreement with Italy's Redelfi

Recently, at The smarter E Europe in Munich, Germany, Qiming Venture Partners portfolio company HyperStrong (688411.SH) formally signed a strategic cooperation framework agreement with Redelfi, a leading Italian energy infrastructure company. Under the agreement, HyperStrong will provide Redelfi with a total of 4.6 GWh of energy storage system solutions for battery energy storage projects developed in Italy**, empowering Italy's grid upgrade with innovative technology and supporting Europe's green energy transition.

HyperStrong's energy storage system solutions will adopt the company's latest modular large-scale storage product, HyperBlock M, featuring high energy conversion efficiency, flexible configuration and scalability, and low land use requirements**, perfectly adapting to Italy's complex geography and grid connection needs. Once operational, the projects will effectively enhance Italy's grid peak shaving and frequency regulation capabilities and renewable energy absorption capacity, providing strong support for the safe and stable operation of power systems in Southern Europe.

Product Launches

01/ UBTECH Officially Releases Wheeled Industrial Humanoid Robot Cruzr Y1

Recently, the OPPO Technology Launch Event and Supply Chain Technology Exhibition officially opened at OPPO's Binhai Bay campus. Qiming Venture Partners portfolio company UBTECH (09880.HK)**'s all-new Cruzr Y1 wheeled industrial humanoid robot made its global debut, demonstrating the full process of bin depalletizing and palletizing on site. As the core heavyweight exhibit in the industrial humanoid track at this OPPO Supply Chain Technology Exhibition, Cruzr Y1 is UBTECH's wheeled industrial humanoid robot designed for industrial scenarios, focusing on solving flexible operation challenges such as handling and sorting of various bins, cartons, and materials, directly addressing core pain points in manufacturing including traditional automation equipment shutting down with slight material misalignment, lengthy changeover and debugging cycles, and single-process-only execution.

**Cruzr Y1 is equipped with domestic computing chips Digua S100P and S600 series, with self-developed hardware architecture and ROSA software system as the core software and hardware foundation, combined with extensive proprietary patents and VLA (Vision-Language-Action) integrated algorithms, creating a full-chain self-developed moat from core components to complete machine systems to scenario algorithms, effectively ensuring product performance, quality, and delivery.

02/ Cix Technology Unveils Digital Employee AI Agent Solution

Recently, Qiming Venture Partners portfolio company Cix Technology jointly launched a digital employee AI agent solution based on its self-developed Cix Agentic SoC P1 chip, in partnership with AI agent development ecosystem partners. The solution leverages advanced holographic perception and local computing power to build industry-specific AI Agents with complete autonomous capabilities, reducing burden and increasing efficiency for industry clients in financial services, government affairs, tax and compliance, human resources, and other sectors with complex and repetitive business processes, achieving intelligent upgrading of full business workflows.

**Currently, this digital employee AI agent has completed deployment validation in two high-compliance, high-standardization business scenarios: financial services and government affairs. The solution focuses on high-frequency repetitive business pain points in these two domains, configuring six dedicated digital employee roles for each, achieving significant efficiency leaps while ensuring full compliance and controllability throughout business processes.

03/ Axera Technology and Fibocom Jointly Release AI Conference Device Solution

Recently, Qiming Venture Partners portfolio company and China's edge AI chip leader Axera Technology (00600.HK) and Fibocom jointly released an AI conference device solution. Fibocom handles the integrated hardware and software design, while Axera Technology provides high-efficiency AI computing chips, aiming to meet the strict requirements of finance, judiciary, enterprise internal control, and professional services industries for data security and localized processing. By enabling conference transcription, content organization, and intelligent minute generation on the device side, the solution promotes the deployment and application of intelligent conference terminals.

In this jointly released AI conference device solution, Fibocom leverages Axera Technology's 18 TOPS@INT8 high-efficiency computing chip for hardware design, system adaptation, model deployment, and product integration, innovatively integrating full-process intelligent conference processing capabilities on the device side to form an efficient application closed loop from information collection to intelligent output.

R&D Progress

01/ Zenitar's "PM+R" Chemotherapy-Free Combination Regimen Approved for Clinical Trials

Recently, Qiming Venture Partners portfolio company Zenitar received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, approving the clinical study of puyisitam mesylate for injection combined with rituximab in relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).

Unlike traditional DLBCL combination chemotherapy regimens, the approved "PM+R" combination is a fully chemotherapy-free regimen. This allows it to avoid severe adverse effects associated with traditional chemotherapy — such as bone marrow suppression, nausea and vomiting, and severe hair loss — providing a new "low-burden" treatment option for patients troubled by multi-drug chemotherapy. This breakthrough represents an important practice of precision medicine's goal to "treat disease while preserving quality of life."

02/

Gan & Lee Pharmaceuticals' Insulin Glargine Injection Approved in Honduras

Recently, Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) announced that its self-developed insulin glargine injection has officially received drug registration approval from Honduras' Agencia de Regulación Sanitaria (ARSA). This approval marks the successful launch of the company's first self-held marketing authorization (MAH) project in Central America, achieving a "zero breakthrough" for the company in the Central American region and laying a solid foundation for further expansion into Latin American markets and deeper regional health cooperation.

As the first Chinese company to master third-generation insulin industrialization technology, Gan & Lee Pharmaceuticals continues to advance global access to high-quality biopharmaceuticals through its full-industry-chain platform covering R&D, manufacturing, and commercialization. The approval of insulin glargine injection in Honduras will further leverage the company's advantages in scaled production and international supply systems, providing long-term, stable product supply for the local market and helping enhance regional resilience in diabetes treatment drug supply.

Technical Capabilities

Daxiao Robotics' "Xiaotu" Launches New Model for 7×24 Autonomous Operation of Robotic Dogs in Open Scenarios

Recently, intelligent robotic dogs equipped with Daxiao Robotics' open-scenario autonomous operation solution — Xiaotu — were officially deployed in Shanghai's West Bund district, fully committed to normalized on-site unmanned patrol operations. The solution consists of two core modules: the embodied super-brain module A1 and the intelligent management and control platform, comprehensively empowering robotic dogs to achieve all-weather, all-scenario, highly intelligent autonomous operations. Robotic dogs equipped with Daxiao's embodied super-brain module A1 have pioneered the industry's first deployment of open-environment autonomous navigation technology, achieving fully autonomous capabilities across all dimensions and fundamentally realizing embodied intelligence serving core urban scenarios.

Drawing on deep technical accumulation, Daxiao Robotics' open-environment autonomous navigation technology eliminates reliance on pre-built high-precision maps, achieving see-and-go autonomous passage capability. The robotic dog can perceive its surrounding environment in real time, identify various dynamic obstacles and irregular passage areas, and quickly complete self-localization, environmental assessment, and dynamic path planning, easily handling complex urban conditions such as mixed pedestrian and vehicle traffic, temporary construction, and pedestrian crossings.

---

Past Issues

Qiming Perspectives | Duane Kuang, Qiming Venture Partners: Embrace the Cycle, Cross the Cycle — AI Will Be an Ultra-Long Technology Cycle Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Companies Vol. 21, 2026.6.23 Qiming Headlines | Qiming Venture Partners and Portfolio Companies Win Multiple Awards Including ChinaVenture's 2025 Best VC Firm TOP4

Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.

To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 companies have become recognized unicorns or super-unicorns in their industries.

Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 0800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu AI (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), Haobio, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.